Se prevé que el mercado de la doxorrubicina alcance los 1.983,40 millones de dólares en 2028 desde los 1.390,64 millones de dólares en 2022. Se espera que registre una tasa compuesta anual del 6,1 % entre 2022 y 2028.
La doxorrubicina pertenece al familia de las antraciclinas y se usa ampliamente para tratar neoplasias malignas, como mama, pulmón, mieloma múltiple, ovario, riñón, hígado, sarcoma y otras. El producto se utiliza en pacientes con cáncer cuya enfermedad ha progresado o recurrido después de la quimioterapia.
El informe ofrece información y un análisis en profundidad del mercado mundial de doxorrubicina, enfatizando varios parámetros, como las tendencias del mercado y los avances tecnológicos. y dinámica del mercado. También proporciona el análisis del panorama competitivo de los principales actores del mercado y el impacto de la pandemia de COVID-19 en el mercado en todas las regiones principales.
La pandemia de COVID-19 alteró las condiciones socioeconómicas de varios países del mundo. El costo de la atención médica general está aumentando significativamente en América del Norte. El sistema de salud de EE. UU. incurrió en un costo directo de 5,3 mil millones de dólares en 2020. El sistema de salud contribuyó con 60 mil millones de dólares además de los costos anuales generales del país en 2020. Más del 40% de la población de América del Norte canceló sus citas en 2020, y el 13% informó que necesitaba atención pero no la programó ni la recibió. La pandemia de COVID-19 alteró las condiciones económicas y los comportamientos sociales en los países de América del Norte. Las medidas de contención promulgadas por los gobiernos para mitigar la propagación de enfermedades cambiaron el patrón de prestación de servicios de salud en Estados Unidos. Según el Departamento de Medicina de Emergencia, en muchas ciudades del país, las visitas al departamento de emergencias (ED) disminuyeron aproximadamente un 40 % en 2020. Además, las citas ambulatorias y los tratamientos electivos se pospusieron o reemplazaron por prácticas de telemedicina.
Perspectivas estratégicas
En noviembre de 2021, Pfizer Inc. anunció el candidato antiviral oral en investigación para la COVID-19, PAXLOVID. Basado en un análisis provisional de la Evaluación de Fase 2/3 de la Inhibición de la Proteasa para COVID-19 en Pacientes de Alto Riesgo (EPIC-HR), que es un estudio aleatorizado, doble ciego de pacientes adultos con COVID-19 no hospitalizados que fueron con un alto riesgo de progresar a una enfermedad grave, la vacuna PAXLOVID supuestamente redujo la hospitalización y la muerte. Hubo limitaciones de suministro relacionadas con la producción de vacunas en los primeros meses de 2021. Sin embargo, la instalación de nuevas plantas y la promoción de cambios tecnológicos son las estrategias que respaldan la producción de dosis de refuerzo en EE. UU. y Canadá, junto con sus planes de administración.
Además, se creó una situación caótica en la industria de la salud en todos los países, lo que provocó una reducción del número de consultas y un menor número de casos de cáncer diagnosticados. Por ejemplo, los esfuerzos internacionales sugieren que los diagnósticos de cáncer se redujeron en un 40% entre el 9 de marzo de 2020 y el 17 de mayo de 2020, en comparación con los diagnósticos promediados durante el mismo período en 2018 y 2019. En su interrupción de los ensayos clínicos y el suministro de medicamentos Para los pacientes, la pandemia de COVID-19 ha impactado las áreas más cruciales del mercado global de doxorrubicina.
Según la región, el mercado global de doxorrubicina está segmentado en América del Norte, Europa, Asia Pacífico, Medio Oriente y África y América del Sur y Central.
regiones lucrativas para el mercado mundial de doxorrubicina
Perspectivas del mercado
La creciente prevalencia del cáncer impulsa el mercado mundial de doxorrubicina
El cáncer es una de las principales causas de muerte a nivel mundial. Según la Organización Mundial de la Salud (OMS), el cáncer fue la primera causa de muerte en personas menores de 70 años en 183 países y la cuarta causa de muerte entre la población de todas las edades en 123 países en todo el mundo en 2019. Además, como Según los datos publicados por la OMS en marzo de 2021, diferentes tipos de cáncer habrán causado ~10 millones de muertes en 2020. La creciente prevalencia del cáncer ha sobrecargado los sistemas de salud en todo el mundo, lo que ha reforzado la demanda de quimioterapia. La doxorrubicina es uno de los principales fármacos utilizados como tratamiento de primera línea en quimioterapia. El fármaco se utiliza para inducir la regresión en enfermedades neoplásicas diseminadas como mama, ovario, vejiga de células de transición, tiroides, gástrica, leucemia linfoblástica aguda, leucemia mieloblástica aguda, tumor de Wilms, neuroblastoma, sarcomas de tejidos blandos y huesos, enfermedad de Hodgkin, linfoma maligno, y carcinomas broncogénicos, en los que el tipo histológico de células pequeñas. El fármaco también se recomienda como terapia adyuvante en mujeres a las que se les ha extirpado un cáncer de mama primario y que tienen afectación de los ganglios linfáticos axilares.
Según Cancer Statistics, 2022, publicado en la revista de la Sociedad Estadounidense del Cáncer, datos de De 2015 a 2019 indicaron un aumento anual del 0,5% en el cáncer de mama femenino. Al mismo tiempo, la incidencia del cáncer de próstata se mantuvo estable. Por lo tanto, se prevé que el creciente número de pacientes con cáncer en todo el mundo impulsará el crecimiento del mercado mundial de doxorrubicina.
Información basada en la formulación de medicamentos
Basado en la formulación de medicamentos, el mercado mundial de doxorrubicina se divide en liofilizados. Inyección de polvo y doxorrubicina. En 2022, el segmento de polvo liofilizado representó una mayor cuota de mercado. La posición de mercado de este segmento se debe a la creciente prevalencia del cáncer, la estabilidad del almacenamiento y la creciente preferencia por la quimioterapia.
Información basada en aplicaciones
Basado en la aplicación, el mercado global de doxorrubicina se segmenta en cáncer de pulmón, sarcoma, cáncer de mama, mieloma múltiple, cáncer de ovario, cáncer de riñón, leucemia, cáncer de hígado y otros. Es probable que el segmento de cáncer de mama domine el mercado en 2022.
Información basada en el canal de distribución
Según el canal de distribución, el mercado mundial de doxorrubicina se ha clasificado en farmacia hospitalaria, venta minorista farmacia y farmacia en línea. Se espera que el segmento de farmacia hospitalaria tenga la mayor participación de mercado en 2022.
Mercado global de doxorrubicina, por canal de distribución: 2022 y 2028
Los actores del mercado global de doxorrubicina adoptan estrategias orgánicas, como el lanzamiento y la expansión de productos, para aumentar su huella y su cartera de productos. en todo el mundo.
Por geografía, América del Norte se segmenta aún más en EE. UU., Canadá y México. Europa se bifurca en Francia, Alemania, Italia, Reino Unido, España y el resto de Europa. APAC se divide en China, India, Corea del Sur, Japón, Australia y el resto de APAC. Oriente Medio y África está segmentado en Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos y el resto de MEA. América Central y del Sur está segmentada en Brasil, Argentina y el resto de SCAM.
Algunos de los principales actores que contribuyen al mercado de la doxorrubicina son Accord Healthcare, Cipla, Inc, Dr. Reddy, Cadila Pharmaceuticals, Meiji Seika Pharma Co, Janseen Pharmaceuticals (Johnson and Johnson Services, Inc.), Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd, Baxter International Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Doxorubicin belongs to the anthracycline family and is widely used for the treatment of malignancies such as breast, lung, multiple myeloma, ovarian, kidney, liver, sarcoma, and others. The product is used in patients with cancer whose disease has progressed or recurred after chemotherapy.
Increasing prevalence of cancer and increasing preference of chemotherapy is one of the most significant factors responsible for the overall market growth.
Based on drug formulation, lyophilized powder dominated the market by accounting largest share in 2022 and is expected to continue to do so till the forecast period.
The breast cancer segment dominated the global doxorubicin market and accounted for the largest revenue of US $316.32 million in 2022.
Accord Healthcare, Cipla Inc., Dr. Reddy’s Laboratories, Meiji Holdings Co., Ltd., Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.), Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Baxter International Inc., Zydus Cadila are among the leading companies operating in the global doxorubicin market
Global doxorubicin market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. In North America, the U.S. is the largest market for doxorubicin market. The US is estimated to hold the largest share in the doxorubicin market during the forecast period. The presence of top players and favorable regulations related to product approvals coupled with commercializing new products are the contributing factors for the regional growth. Additionally, the increasing number of technological advancements is the key factor responsible for the Asia-Pacific regional growth for doxorubicin accounting fastest growth of the region during the coming years.
The List of Companies - Doxorubicin Market
- Accord Healthcare
- Cipla Inc.
- Dr. Reddy's Laboratories
- Meiji Holdings Co., Ltd.
- Janssen Pharmaceuticals (Johnson and Johnson Services, Inc.)
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Baxter International Inc.
- Zydus Cadila
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jul 2022
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jul 2022
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jul 2022
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jul 2022
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jul 2022
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jul 2022
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jul 2022
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jul 2022
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)